Dealmaking

Dealmakers hold off on launching deals, and due diligence is taking longer in uncertain environment

Insights from dealmakers who attended ACG’s DealMax 2025 conference in Las Vegas; an update on companies for sale coverage; thoughts from an industrials-focused investment banker on how the tariff rollercoaster is affecting dealmaking in that sector.

Bain’s Giovanni Camera reveals Namirial growth plans; IPO processes delayed, says EY report

Namirial specializes in software that enables enterprises to verify identities, authenticate signatures and certify transactions.

Bain Capital eyes global expansion for Namirial amid rising digital security demands

Namirial is a digital transaction management business based in Italy.

Optimism for take-private deals after Sycamore’s move for Walgreens Boots Alliance; Steady stream of food-service deals continue in 2025

Michael Blankenship, co-chair of Winston & Strawn’s capital markets practice and Houston managing partner, on take-private deals in private equity this year; the subsector of food-service and why it’s attractive to PE firms; Bain Capital's deal for HealthEdge, a Burlington, Massachusetts-based healthcare tech company.

SVP, Blantyre buy global chemicals biz; EQT nears exit of E45 moisturizer producer Karo to KKR, say sources; KKR, Stonepeak bid wins Assura board backing

OQ Chemicals is a global producer and merchant of oxo chemicals.

Dealmakers more cautious than a week ago; why Goldman Sachs, Shore Capital back autism care

Lead Edge Capital explains how tariffs and the stock market turmoil are affecting dealmaking.

Autism care supply-demand imbalance is driving PE investments

Calex Partners, Goldman Sachs and Shore Capital are investing in autism care.

Private equity taps into Europe’s diversified approach to energy; LDC’s RDi completes add-on

LDC portfolio company RDi has completed the acquisition of Inicio Health, a UK-based clinically led healthcare company.

‘New kind of optimism’ in Europe's energy sector

'The industry has not had this kind of impetus for the 20 years I’ve worked in the space,' says Lincoln International's Carlos Candil.

Hamilton Lane’s Erik Hirsch: 'private markets, particularly private equity, outperform by the greatest amount' in down periods; what’s your take?

How are the tariffs affecting dealmaking in the sectors you invest in? How are they affecting deals already in the works? How are they affecting your portfolio companies? What strategies are you deploying to handle them? What targets have become less attractive, what targets have become more attractive?